https://www.selleckchem.com/pr....oducts/mi-773-sar405
In this study we report reprogramming and generation of a new human induced pluripotent stem cell line UOMi009_A, which was generated from a 64 year old male patient with childhood onset Hypophosphatasia (HPP). The patient has compound heterozygous mutations in the ALPL gene (c.571GA (p.Glu191Lys) and c.1001GA (p.Gly334Asp)) which were confirmed in the UOMi009_A line. This line was well characterized and will help in our future assessment of HPP disease pathophysiology and drug screening.Tyre wear particles (TWP) are so
Curtir
Comentario
Compartilhar
